Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000578777 | SCV000680596 | pathogenic | not provided | 2017-12-06 | criteria provided, single submitter | clinical testing | The R180X nonsense variant has been reported previously in association with 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency (Stadler et al., 2006; Grunert et al., 2012). This pathogenic variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. |
Labcorp Genetics |
RCV001066211 | SCV001231216 | pathogenic | 3-methylcrotonyl-CoA carboxylase 2 deficiency | 2025-01-23 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg180*) in the MCCC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MCCC2 are known to be pathogenic (PMID: 11181649, 22642865). This variant is present in population databases (rs780011606, gnomAD 0.006%). This premature translational stop signal has been observed in individuals with 3-methylcrotonyl-CoA carboxylase deficiency (PMID: 16835865, 22642865). ClinVar contains an entry for this variant (Variation ID: 488740). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV001066211 | SCV001810490 | pathogenic | 3-methylcrotonyl-CoA carboxylase 2 deficiency | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001066211 | SCV004194378 | pathogenic | 3-methylcrotonyl-CoA carboxylase 2 deficiency | 2024-01-12 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001271399 | SCV001452525 | pathogenic | Methylcrotonyl-CoA carboxylase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |